Clinical trials: Anthracycline-induced Cardiotoxicity
Lymphoma, Large B-Cell
Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec.
- Conditions
- Lymphoma, Large B-Cell, Diffuse Large B-Cell
- Trial name
- NCT02916316
- Testing
- R-CHOP with doxorubicin
- Where
- 18 sites in Italy
- Volunteers
- 127 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Cardiotoxicity
Remote Ischaemic Preconditioning in Childhood Cancer
Survival rates of children with cancers have improved significantly in the recent few decades. Nonetheless, the side effect of this class of drugs on heart function remains to be an issue of concern.
- Trial name
- NCT03166813
- Testing
- Remote Ischaemic Preconditioning, Control
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- The University of Hong Kong
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Neoplasms
Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
In the context of breast cancer, in case of an indication for chemotherapy, anthracycline-based protocols make it possible to improve the overall survival of patients most at risk.
- Trial name
- SCARA-B (NCT06443645)
- Testing
- Anthracycline
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Paul Strauss
Childhood Cancer, Cardiac Toxicity
Translating ECHOS2 Into an mHealth Platform
Childhood cancer survivors are at an increased risk of cardiac toxicity due to prior anti-cancer therapy. However, adherence to cardiac screening in this population remains low.
- Conditions
- Childhood Cancer, Cardiac Toxicity, Pediatric Cancer
- Trial name
- ECHOS2 (NCT05923242)
- Testing
- Computerized Intervention Authoring Software (CIAS)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Washington University School of Medicine
Cardiotoxicity, Heart Failure
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated with severe cardiovascular adverse effects, including heart failure.
- Conditions
- Cardiotoxicity, Heart Failure, Neoplasms, Breast Neoplasms
- Trial name
- ML-CardioTox (NCT07191730)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Caen
Cancer and / or Hematological Malignancy, Anthracycline-induced Cardiotoxicity
BHF-COLLATE: UK Prospective, Multi-centre, Observational, Cardio-oncology Anthracycline Registry
The study aims to collect information on how cancer treatment affects heart health. This will include collecting baseline medical information, storing blood samples, recording cancer treatment, and analysing heart scans across…
- Trial name
- BHF-COLLATE (NCT07864467)
- Where
- 6 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Cardiovascular Diseases
Assessment of Global Longitudinal Strain for the Prediction of Anthracycline Induced Cardiotoxicity
Anthracycline therapy is well-known for its adverse cardiac effects. Anthracycline-induced cardiotoxicity (AIC) is associated with a poor prognosis; since classical heart failure treatment can potentially reverse cardiac…
- Trial name
- Anthracardio (NCT02875171)
- Testing
- Anthracycline administration
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Versailles Hospital
Breast Cancer, Metastatic Breast Cancer
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity
- Trial name
- NARNIA (NCT05732051)
- Testing
- Nicotinamide Riboside
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- University Hospital, Akershus
Breast Cancer
Cardiotoxicity of Cancer Therapy (CCT)
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy…
- Trial name
- NCT01173341
- Testing
- Echocardiography, Blood Collection, Symptoms Questionnaire
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Aerobic Exercise in Patients Receiving Chemotherapy for Cancer
RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works…
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00728429
- Testing
- exercise intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab.
- Trial name
- PROTECT (NCT06341842)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity
Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity
Anthracyclines, such as doxorubicin, are effective anticancer agents but may cause dose-dependent cardiac injury, including early changes in left ventricular function and cardiac biomarkers.
- Trial name
- DAPA-AIC (NCT06888505)
- Testing
- Dapagliflozin (Forxiga)
- Where
- Iraq
- Volunteers
- 94 people
- Sponsor
- Hawler Medical University
Breast Cancer
Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy
the study aim to protect patients received anthracyclines containing chemotherapy from cardiotoxcity induced by anthracyclines derivatives.
- Trial name
- NCT04434404
- Testing
- L-Carnitine 500Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 83 people
- Sponsor
- Horus University
Cancer, Heart Failure
Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study
Anthracycline (AC) chemotherapy has substantially reduced the mortality rate from several common cancers globally. Unfortunately, AC treatment is associated with up to 19% risk of heart failure (HF).
- Conditions
- Cancer, Heart Failure, Cardiotoxicity
- Trial name
- SPARE-HF (NCT03186404)
- Testing
- Atorvastatin
- Where
- Canada
- Volunteers
- 112 people
- Sponsor
- University Health Network, Toronto
Cardiotoxicity, Neoplasms
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
The goal of this clinical trial is to evaluate the effect of spironolactone in the primary prevention of cardiotoxicity in cancer patients who are undergoing chemotherapy with anthracycline within 12 months.
- Conditions
- Cardiotoxicity, Neoplasms, Chemotherapy Effect, Heart Failure
- Trial name
- SPIROTOX (NCT06005259)
- Testing
- Spironolactone
- Where
- Brazil
- Volunteers
- 264 people
- Sponsor
- University of Sao Paulo
Childhood Cancer Survivors, Cardiotoxicity
Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial
This trial aims to evaluate the impact of exercise intensity on cardiac health in young adult survivors of childhood cancer previously treated with anthracyclines.
- Conditions
- Childhood Cancer Survivors, Cardiotoxicity, Cardiovascular Diseases, Anthracycline-induced Cardiotoxicity
- Trial name
- PULSE (NCT07442578)
- Testing
- HIIT Exercise Program, MICT Exercise Program
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Therapy-Related Cardiac Dysfunction
Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab
This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with…
- Trial name
- CARPTOX-BC (NCT06881940)
- Testing
- Rehabilitation Program, No Rehabilitation Program
- Where
- 2 sites in Mexico
- Volunteers
- 284 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Breast Neoplasm Female, Lymphoma
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women.
- Conditions
- Breast Neoplasm Female, Lymphoma, Cardiotoxicity, Anthracyclines
- Trial name
- NCT03850171
- Testing
- Exercise Training
- Where
- 4 sites in Switzerland
- Volunteers
- 57 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Heart Failure, Anthracycline-induced Cardiac Toxicity
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused…
- Conditions
- Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD), Arterial Stiffness
- Trial name
- Alpaca (NCT07245069)
- Testing
- Dapagliflozin 10 mg
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana